Drugs / SY-5007
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06352190 | May → Jun 2024 | — | Shouyao Holdings (Beijing) Co. LTD | Unknown | No outcome recorded |
| Phase 1 | NCT06325761 | Apr → May 2024 | — | Shouyao Holdings (Beijing) Co. LTD | Unknown | No outcome recorded |
| Phase 1 | NCT06332053 | Apr → Jun 2024 | — | Shouyao Holdings (Beijing) Co. LTD | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05278364 | Apr 2021 → Jan 2025 | medullary thyroid gland carcinoma, non-small cell lung carcinoma | Shouyao Holdings (Beijing) Co. LTD | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06031558 | Oct 2023 → Apr 2025 overdue | non-small cell lung carcinoma | Shouyao Holdings (Beijing) Co. LTD | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SY-5007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05278364 ↗ |
| Action | Inhibit | “a RET selective Inhibitor” NCT05278364 ↗ |
| Route | Oral | “SY-5007 administered orally” NCT05278364 ↗ |
| Target | RET | “a RET selective Inhibitor” NCT05278364 ↗ |